Clinical Trial Alert: Alexion Pharmaceuticals Seeks Participants for a Phase 3 Pediatric Myasthenia Gravis Study
Researchers at Alexion Pharmaceuticals are looking for children with generalized myasthenia gravis (gMG) to participate in an open-label Phase 3 study. The goal of the study is to evaluate the safety and efficacy of eculizumab (Soliris) in pediatric patients. This therapy may improve muscle strength by reducing inflammation caused by the immune system.
All participants will receive eculizumab. At the end of the second treatment period, subjects will be given the option of enrolling in a long-term extension study.
The total study duration for each patient will be up to 4.7 years, with clinic visits every two weeks. The primary endpoint for efficacy is the change from baseline in the quantitative myasthenia gravis (QMG) total score. Throughout the study, participants will continue to see their regular doctor for routine care.
Do you have a child with Myasthenia Gravis? What do you think about this trial?
Sorry, there were no replies found.
Log in to reply.